TGTX Stock Surges As Briumvi Pipeline Momentum Accelerates

TG Therapeutics Inc. stocks have been trading up by 8.58 percent after pivotal positive clinical trial news boosted investor confidence.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TGTX

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Phase 3 ENHANCE data showed a new single 600 mg Day 1 Briumvi infusion is bioequivalent to the current two-step regimen, with similar safety and no new signals.
Positive Phase 1 subcutaneous Briumvi data in multiple sclerosis showed strong bioavailability, clean safety, and supports at-home self-administration, with Phase 3 already fully enrolled.
A pooled ULTIMATE I & II analysis found Briumvi delivered better clinical and MRI outcomes than teriflunomide in treatment‑naive relapsing MS, including early‑disease patients.
In myasthenia gravis, early subcutaneous Briumvi data were strong, backing a new Phase 2 maintenance trial after efgartigimod induction.
TGTX shares have reacted sharply to this news flow, including an intraday jump of about 10.6% to roughly $40.53 and multiple double‑digit premarket spikes.

Live Update At 14:03:19 EDT: On Wednesday, June 10, 2026 TG Therapeutics Inc. stock [NASDAQ: TGTX] is trending up by 8.58%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TG Therapeutics, trading as TGTX, is acting like a biotech name with both real revenue and real momentum. The company booked about $204.9M in total revenue last quarter and posted net income of $19.8M. For a high‑growth biotech, that is a big shift from pure cash burn to actual profitability.

Margins are aggressive. TGTX reports gross margin around 92.6%, meaning most of each sales dollar from Briumvi drops through after manufacturing costs. Operating margin near 19% shows the business can stay in the green even while it pours money into sales and R&D.

On the balance sheet, TGTX holds roughly $442.2M in cash and cash equivalents against $751.7M of long‑term debt. Current ratio about 5.8 signals plenty of near‑term liquidity, but traders still need to respect leverage.

The market is not ignoring this story. With price‑to‑sales around 7.7 and a P/E near 11.8, traders are paying up for Briumvi’s growth but not at bubble levels compared to some biotech peers. Strong returns on equity above 100% reflect how quickly TGTX is turning its capital into earnings.

More Breaking News

On the chart, TGTX has ripped from closes around $38–40 in late May to $47.09 on 2026/06/10, a breakout move backed by news rather than rumor.

Why Traders Are Watching TGTX Right Now

TGTX is a classic example of how clinical catalysts and chart momentum can line up at the same time. The core of the story is Briumvi, the company’s anti‑CD20 therapy already approved in relapsing multiple sclerosis. Over the past few weeks, TG Therapeutics has stacked one positive data point on top of another, and traders have noticed.

First, the Phase 3 ENHANCE trial delivered what Wall Street likes to see: de‑risking. ENHANCE showed that a single 600 mg Day 1 infusion of Briumvi is bioequivalent to the current split‑dose regimen, with similar MRI and safety outcomes. For TGTX, that sets up a cleaner label and a simpler start for new patients. For traders, it reduces uncertainty and supports the long‑term Briumvi revenue curve.

Second, the subcutaneous push is the real upside sizzle. Multiple Phase 1 readouts showed high‑concentration, low‑volume subcutaneous Briumvi with more than 60% bioavailability, similar B‑cell depletion to IV, and a clean tolerability profile. Management is already guiding toward Phase 3 completion with topline data expected in late 2026 or early 2027 and potential approval around 2028.

The key trading angle: at‑home, self‑administered Briumvi, possibly quarterly. TG Therapeutics believes this could nearly double the drug’s addressable market. The market reaction backs that view. TGTX jumped more than 10% in several sessions on the subcutaneous news and climbed over 10% intraday to roughly $40.53 as the positive headlines piled up.

Add in expansion beyond MS. Early Phase 1 data in myasthenia gravis showed rapid, meaningful MG‑ADL improvements and supported a new Phase 2 maintenance trial after efgartigimod induction. That gives TGTX another shot on goal and keeps the news pipeline full.

Conclusion

For active traders, TGTX sits at the crossroads of strong fundamentals and headline‑driven volatility. The company has real revenue, high margins, and positive earnings, but the stock still trades like a catalyst vehicle because so much value rests on Briumvi’s growth path.

Short term, TGTX’s daily chart shows a decisive breakout. The stock moved from the high‑30s base to a high near $49.30 on 2026/06/10, with intraday action holding the mid‑$40s for most of the session. The 5‑minute tape shows steady higher lows after the morning surge, signaling dip buyers were in control rather than profit‑takers. For momentum traders, that pattern is exactly what they look for after a news‑driven gap.

Medium term, the Phase 3 ENHANCE success, the subcutaneous Briumvi program, and the myasthenia gravis expansion all pull the TGTX story in the same direction: larger, more durable Briumvi revenue. Every clean data update or regulatory milestone has the potential to act as another spark on the chart.

But traders still need discipline. Biotech names like TGTX can swing hard on any safety signal or delayed readout. As Tim Sykes likes to remind his community, “The market rewards traders who prepare, not those who hope. Focus on the pattern, the catalyst, and always cut losses quickly.” In the same spirit, as Tim Bohen, lead trainer with StocksToTrade says, “Preparation is half the trade. By the time the bell rings, my decisions are nearly made.”. This TGTX run offers a live case study in exactly that mindset—study the news, respect the risk, and let the price action confirm your plan.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!